Industry news that matters to you.  Learn more

Archives for October 2015

SeraCare Launches New Quantitative Reference Materials for NGS-Based Tumor Profiling Assays

SeraCare Life Sciences, a leading partner to global in vitro diagnostics manufacturers, announced today that the company’s precision medicine business unit has launched its second product in a growing line of reference materials for next-generation sequencing (NGS)-based tumor profiling assays. The SeraseqTM Solid Tumor Mutation Mix-I (AF1-10) contains the same mixture of mutations in key oncogenes and tumor suppressor genes as in the previously launched AF20 mix, but is offered at five additional allele frequencies.

Science Academies Highlight Importance of Precision Medicine at EU Parliament

For the first time policy makers, patients, industry representatives and the scientific allergy and asthma community came together at the European Parliament to discuss the need for Precision Medicine. A recent symposium on the “European need for precision medicine in allergy and airways diseases” laid the foundation to define an action plan on how to deliver the cost-effective precision medicine to the allergic patient.

Veracyte CEO Bonnie Anderson Urges CMS to Reverse Its Proposed 2016 Pricing Methodology for Advanced Molecular Diagnostic Tests

Veracyte, Inc. (NASDAQ: VCYT) announced that Bonnie Anderson, president and chief executive officer, today urged the Centers for Medicare and Medicaid Services (CMS) to reverse its proposed 2016 pricing methodology for precision medicine tests, including the company’s Afirma® Gene Expression Classifier (GEC). She spoke at a public meeting of CMS’s Advisory Panel on Clinical Laboratory Diagnostic Tests, held in Baltimore, Md.

Genospace Partner Sequence Bio Announces Initiative with Government of Newfoundland and Labrador on Large-Scale Precision Medicine Initiative

Genospace, a precision medicine software company that has developed a comprehensive suite of tools enabling the broad use of genomic and other biomedical data in research and clinical care, today announced that Sequence Bioinformatics, Inc. and the Government of Newfoundland and Labrador have selected Genospace Population Analytics™ to support a groundbreaking precision medicine initiative.

Sequenom To Explore The Clinical Utility Of A Novel Liquid Biopsy Assay In Melanoma Patients In Collaboration With University Of Colorado Denver

Sequenom, Inc. (NASDAQ: SQNM), a life sciences company committed to enabling healthier lives through the development of innovative products and services, today announced that it has entered into a clinical collaboration with the University of Colorado Denver, School of Medicine (CU School of Medicine). Under this collaboration, CU School of Medicine will explore the utility of Sequenom’s research use only (RUO) liquid biopsy assay to determine whether ctDNA profiling can be used to monitor treatment response and relapse in melanoma patients. This technology has the potential to overcome the challenges and limitations associated with current methods to monitor treatment response such as invasive biopsies and repeated imaging studies.